Harbor Capital Advisors Inc. Invests $736,000 in Moderna, Inc. (NASDAQ:MRNA)

Harbor Capital Advisors Inc. acquired a new position in Moderna, Inc. (NASDAQ:MRNA) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 6,060 shares of the company’s stock, valued at approximately $736,000.

Other large investors have also recently modified their holdings of the company. ICA Group Wealth Management LLC purchased a new position in shares of Moderna in the fourth quarter worth about $27,000. GHP Investment Advisors Inc. increased its holdings in Moderna by 208.3% during the 1st quarter. GHP Investment Advisors Inc. now owns 185 shares of the company’s stock valued at $28,000 after purchasing an additional 125 shares during the period. Stone House Investment Management LLC purchased a new position in Moderna during the 1st quarter valued at about $36,000. Heritage Wealth Management LLC increased its holdings in Moderna by 100.0% during the 4th quarter. Heritage Wealth Management LLC now owns 226 shares of the company’s stock valued at $41,000 after purchasing an additional 113 shares during the period. Finally, Stonebridge Capital Advisors LLC increased its holdings in Moderna by 79.1% during the 1st quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock valued at $49,000 after purchasing an additional 125 shares during the period. Hedge funds and other institutional investors own 64.51% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research analyst reports. 51job restated an “upgrade” rating on shares of Moderna in a report on Monday, June 26th. Royal Bank of Canada reduced their price target on Moderna from $200.00 to $190.00 and set an “outperform” rating on the stock in a report on Friday, August 4th. Deutsche Bank Aktiengesellschaft downgraded Moderna from a “buy” rating to a “hold” rating and reduced their price target for the company from $200.00 to $125.00 in a report on Thursday, August 3rd. HSBC initiated coverage on Moderna in a research report on Friday, July 14th. They set a “reduce” rating and a $97.00 price objective on the stock. Finally, UBS Group raised Moderna from a “neutral” rating to a “buy” rating and cut their price objective for the company from $221.00 to $191.00 in a research report on Monday, June 26th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $155.52.

Moderna Stock Performance

Shares of MRNA opened at $104.14 on Tuesday. The company has a quick ratio of 3.16, a current ratio of 3.39 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average price is $112.49 and its 200-day moving average price is $127.70. Moderna, Inc. has a 52 week low of $95.02 and a 52 week high of $217.25. The stock has a market cap of $39.63 billion, a P/E ratio of 38.43 and a beta of 1.63.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($3.62) EPS for the quarter, topping analysts’ consensus estimates of ($3.84) by $0.22. Moderna had a return on equity of 6.62% and a net margin of 11.33%. The firm had revenue of $344.00 million for the quarter, compared to analysts’ expectations of $307.67 million. During the same period in the previous year, the firm posted $5.24 EPS. The business’s revenue for the quarter was down 92.8% compared to the same quarter last year. Equities research analysts anticipate that Moderna, Inc. will post -4.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Stephane Bancel sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 21st. The shares were sold at an average price of $121.98, for a total value of $4,879,200.00. Following the completion of the transaction, the chief executive officer now directly owns 5,411,946 shares in the company, valued at approximately $660,149,173.08. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $120.60, for a total value of $1,809,000.00. Following the completion of the transaction, the president now directly owns 1,602,303 shares in the company, valued at approximately $193,237,741.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Stephane Bancel sold 40,000 shares of the business’s stock in a transaction on Wednesday, June 21st. The shares were sold at an average price of $121.98, for a total transaction of $4,879,200.00. Following the sale, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at $660,149,173.08. The disclosure for this sale can be found here. Insiders sold a total of 289,209 shares of company stock worth $33,877,911 in the last three months. Insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.